Quantcast

Indivor study finds 75% patients abstinent from illicit opioids a full year after receiving 12 monthly doses of Suboclade

Indivior’s “Recover” study found that 75% of patients who had received 12 once-monthly doses of sublocade in a Phase 3 clinical trial were abstinent from illicit opioids for a year after the study ended. In this observational study, abstinence was defined as self-report confirmed by urine drug screen.

Read more